Bepranemab 在前驱期至轻度阿尔茨海默病中的安全性、耐受性与疗效:来自 2 期随机对照试验的启示

Safety, Tolerability, and Efficacy of Bepranemab in Prodromal-to-Mild Alzheimer’s Disease: Insights from a Phase 2 Randomized Controlled Trial

This comprehensive review evaluates bepranemab's safety, tolerability, and efficacy in prodromal-to-mild Alzheimer's disease, highlighting a recent phase 2 RCT showing no significant cognitive benefit despite a favorable safety profile, and discusses future directions for tau-targeted therapies.